EUCTR2014-003231-19-FR进行中（未招募）1 期
A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 776
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age >/= 18 years
- •Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra)
- •Representative tumor specimens as specified by the protocol
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Life expectancy >/= 12 weeks
- •Measurable disease, as defined by RECIST v1.1
- •Adequate hematologic and end organ function
- •Disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC], CarboGem, etc.) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 176
排除标准
- •Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
- •Active or untreated central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments
- •Leptomeningeal disease
- •Malignancies other than UBC within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome or incidental prostate cancer
- •Pregnant and lactating women
- •History of autoimmune disease
- •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
- •Serum albumin < 2.5 g/dL
- •Positive test for HIV and/or active hepatitis B or hepatitis C or tuberculosis
- •Severe infections within 4 weeks prior to Cycle 1, Day 1
- •Significant cardiovascular disease
- •Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
- •Prior allogeneic stem cell or solid organ transplant
- •Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1
- •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
- •Prior treatment with CD137 agonists or immune checkpoint blockade
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GemOx) Versus R-GemOx Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaRelapsed/refractory diffuse large B-cell lymphoma (DLBL)MedDRA version: 21.1Level: LLTClassification code 10012857Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractorySystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10012856Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrentSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864EUCTR2018-003727-10-GBF. Hoffmann-La Roche Ltd216
进行中（未招募）
1 期
A study comparing the clinical benefit and side effects of Atezolizumab to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.ON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILUREMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864EUCTR2013-003331-30-DEF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaRelapsed or refractory diffuse large B-cell lymphomaMedDRA version: 20.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2020-001021-31-DEF. Hoffmann-La Roche Ltd274
进行中（未招募）
1 期
Study of Atezolizumab (ANTI PD-L1 ANTIBODY) in Patients with High-risk Muscle-invasive Urothelial Carcinoma after Surgical ResectioMuscle-invasive urothelial carcinomaMedDRA version: 20.0Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2014-005603-25-NLF. Hoffmann-La Roche Ltd800
进行中（未招募）
1 期
A study comparing the clinical benefit and side effects of MPDL3280A to docetaxel in patients with lung cancer who have not benefited from platinum-containing cancer drugs.ON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILUREMedDRA version: 16.1 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864EUCTR2013-003331-30-ESRoche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd1,225